{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:32:05Z","timestamp":1793831525264,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Changsha Natural Science Foundation Project","award":["kq2007058"],"award-info":[{"award-number":["kq2007058"]}]},{"name":"Scientific Research Project of Hunan Provincial Health Commission","award":["D202302066995"],"award-info":[{"award-number":["D202302066995"]}]},{"name":"the Cutting-edge Cancer Support Treatment Research Project","award":["CPHCF-2023-023"],"award-info":[{"award-number":["CPHCF-2023-023"]}]},{"name":"Beijing Medical Award Foundation-China Endocrine Targeted Therapy Research Fund for Advanced breast cancer","award":["YXJL-2020-0941-0747"],"award-info":[{"award-number":["YXJL-2020-0941-0747"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22559-1","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:51:32Z","timestamp":1762282292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic and predictive significance of neutrophil\/lymphocyte ratio for trastuzumab treatment efficacy in HER2-positive breast cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Jing","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouman","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"22559_CR1","doi-asserted-by":"publisher","unstructured":"Zhu, J. et al. Neoadjuvant efficacy of three targeted therapy strategies for HER2-Positive breast cancer based on the same chemotherapy regimen. Cancers (Basel). 14 https:\/\/doi.org\/10.3390\/cancers14184508 (2022).","DOI":"10.3390\/cancers14184508"},{"key":"22559_CR2","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/curroncol29030154","volume":"29","author":"LM Badau","year":"2022","unstructured":"Badau, L. M. et al. Management of HER2-Positive breast cancer for a young patient with visceral Crisis-The adjuvant role of lifestyle changes. Curr. Oncol. 29, 1890\u20131901. https:\/\/doi.org\/10.3390\/curroncol29030154 (2022).","journal-title":"Curr. Oncol."},{"key":"22559_CR3","doi-asserted-by":"publisher","unstructured":"Sun, W. et al. CD40\u00d7HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer. J. Immunother Cancer. 10 https:\/\/doi.org\/10.1136\/jitc-2022-005063 (2022).","DOI":"10.1136\/jitc-2022-005063"},{"key":"22559_CR4","doi-asserted-by":"publisher","first-page":"e30922","DOI":"10.1097\/md.0000000000030922","volume":"101","author":"J Wu","year":"2022","unstructured":"Wu, J., Xie, Z., Xiao, Y., Wang, B. & Zhang, P. Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: A SEER-based study. Medicine (Baltim). 101, e30922. https:\/\/doi.org\/10.1097\/md.0000000000030922 (2022).","journal-title":"Med. (Baltim)."},{"key":"22559_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s10354-010-0838-6","volume":"160","author":"M Hubalek","year":"2010","unstructured":"Hubalek, M., Brunner, C., Matth\u00e4, K. & Marth, C. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med. Wochenschr. 160, 506\u2013512. https:\/\/doi.org\/10.1007\/s10354-010-0838-6 (2010).","journal-title":"Wien Med. Wochenschr"},{"key":"22559_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21, 519\u2013530. https:\/\/doi.org\/10.1016\/s1470-2045(19)30863-0 (2020).","journal-title":"Lancet Oncol."},{"key":"22559_CR7","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/s1470-2045(13)70477-7","volume":"15","author":"G Bianchini","year":"2014","unstructured":"Bianchini, G. & Gianni, L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 15, e58\u201368. https:\/\/doi.org\/10.1016\/s1470-2045(13)70477-7 (2014).","journal-title":"Lancet Oncol."},{"key":"22559_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-021-00629-w","volume":"6","author":"G Zheng","year":"2021","unstructured":"Zheng, G. et al. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal. Transduct. Target. Ther. 6, 236. https:\/\/doi.org\/10.1038\/s41392-021-00629-w (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"22559_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone, M. et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J. Immunother Cancer. 6, 74. https:\/\/doi.org\/10.1186\/s40425-018-0383-1 (2018).","journal-title":"J. Immunother Cancer"},{"key":"22559_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie, G. J. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 88, 218\u2013230. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"22559_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","volume":"19","author":"JL Ethier","year":"2017","unstructured":"Ethier, J. L., Desautels, D., Templeton, A., Shah, P. S. & Amir, E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 19, 2. https:\/\/doi.org\/10.1186\/s13058-016-0794-1 (2017).","journal-title":"Breast Cancer Res."},{"key":"22559_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4048\/jbc.2013.16.1.55","volume":"16","author":"H Noh","year":"2013","unstructured":"Noh, H., Eomm, M. & Han, A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J. Breast Cancer. 16, 55\u201359. https:\/\/doi.org\/10.4048\/jbc.2013.16.1.55 (2013).","journal-title":"J. Breast Cancer"},{"key":"22559_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1245\/s10434-015-4934-0","volume":"23","author":"Y Asano","year":"2016","unstructured":"Asano, Y. et al. Predictive value of Neutrophil\/Lymphocyte ratio for efficacy of preoperative chemotherapy in Triple-Negative breast cancer. Ann. Surg. Oncol. 23, 1104\u20131110. https:\/\/doi.org\/10.1245\/s10434-015-4934-0 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"22559_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12885-020-06750-3","volume":"20","author":"N Ding","year":"2020","unstructured":"Ding, N. et al. Roles of neutrophil\/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy. BMC Cancer. 20, 235. https:\/\/doi.org\/10.1186\/s12885-020-06750-3 (2020).","journal-title":"BMC Cancer"},{"key":"22559_CR15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1245\/s10434-024-16454-8","volume":"32","author":"J Pang","year":"2025","unstructured":"Pang, J. et al. Prognostic value of the baseline systemic Immune-Inflammation index in HER2-Positive metastatic breast cancer: exploratory analysis of two prospective trials. Ann. Surg. Oncol. 32, 750\u2013759. https:\/\/doi.org\/10.1245\/s10434-024-16454-8 (2025).","journal-title":"Ann. Surg. Oncol."},{"key":"22559_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni, L. et al. 5-year analysis of neoadjuvant Pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 17, 791\u2013800. https:\/\/doi.org\/10.1016\/s1470-2045(16)00163-7 (2016).","journal-title":"Lancet Oncol."},{"key":"22559_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","volume":"30","author":"S Maximiano","year":"2016","unstructured":"Maximiano, S., Magalh\u00e3es, P., Guerreiro, M. P. & Morgado, M. Trastuzumab in the treatment of breast cancer. BioDrugs 30, 75\u201386. https:\/\/doi.org\/10.1007\/s40259-016-0162-9 (2016).","journal-title":"BioDrugs"},{"key":"22559_CR18","doi-asserted-by":"publisher","unstructured":"Maadi, H., Soheilifar, M. H., Choi, W. S., Moshtaghian, A. & Wang, Z. Trastuzumab mechanism of Action; 20 years of research to unravel a dilemma. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13143540 (2021).","DOI":"10.3390\/cancers13143540"},{"key":"22559_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","volume":"94","author":"L Arnould","year":"2006","unstructured":"Arnould, L. et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer. 94, 259\u2013267. https:\/\/doi.org\/10.1038\/sj.bjc.6602930 (2006).","journal-title":"Br. J. Cancer"},{"key":"22559_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1479-5876-6-25","volume":"6","author":"A Beano","year":"2008","unstructured":"Beano, A. et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J. Transl Med. 6, 25. https:\/\/doi.org\/10.1186\/1479-5876-6-25 (2008).","journal-title":"J. Transl Med."},{"key":"22559_CR21","doi-asserted-by":"publisher","unstructured":"Ozel, I. et al. The Good, the Bad, and the ugly: Neutrophils, Angiogenesis, and cancer. Cancers (Basel)  14. https:\/\/doi.org\/10.3390\/cancers14030536 (2022).","DOI":"10.3390\/cancers14030536"},{"key":"22559_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","volume":"18","author":"MA Cupp","year":"2020","unstructured":"Cupp, M. A. et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 18, 360. https:\/\/doi.org\/10.1186\/s12916-020-01817-1 (2020).","journal-title":"BMC Med."},{"key":"22559_CR23","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.2147\/ott.S108419","volume":"9","author":"B Wei","year":"2016","unstructured":"Wei, B. et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. Onco Targets Ther. 9, 5567\u20135575. https:\/\/doi.org\/10.2147\/ott.S108419 (2016).","journal-title":"Onco Targets Ther."},{"key":"22559_CR24","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.2147\/cmar.S187233","volume":"11","author":"J Hong","year":"2019","unstructured":"Hong, J. et al. A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab. Cancer Manag Res. 11, 3371\u20133379. https:\/\/doi.org\/10.2147\/cmar.S187233 (2019).","journal-title":"Cancer Manag Res."},{"key":"22559_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1186\/s12885-018-4888-2","volume":"18","author":"K Araki","year":"2018","unstructured":"Araki, K. et al. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with Pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer. 18, 982. https:\/\/doi.org\/10.1186\/s12885-018-4888-2 (2018).","journal-title":"BMC Cancer"},{"key":"22559_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13075-023-03016-8","volume":"25","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Elevated serum Immunoglobulin level predicts high risk of 1-year recurrence in patients with Takayasu arteritis. Arthritis Res. Ther. 25, 36. https:\/\/doi.org\/10.1186\/s13075-023-03016-8 (2023).","journal-title":"Arthritis Res. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22559-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22559-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22559-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:51:34Z","timestamp":1762282294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22559-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22559"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22559-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Xiangya Hospital (202002021), and conducted under the guidance of Declaration of Helsinki. Informed consent was obtained from all patients at the time of database creation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"38570"}}